| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Ban M, Petrié Miše B, Vrdoljak E. Early HER2-positive breast cancer: current treatment and novel approaches[J]. Breast Care (Basel), 2020, 15(6): 560-569.
|
| [3] |
Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer[J]. Chin Clin Oncol, 2020, 9(3): 32.
|
| [4] |
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet, 2017, 389(10075): 1195-1205.
|
| [5] |
Hatschek T, Foukakis T, Bjöhle J, et al. Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: A phase 2 randomized clinical trial[J]. JAMA Oncol, 2021, 7(9): 1360-1367.
|
| [6] |
Cai X, Liu C, Zhang TN, et al. Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion[J]. J Cell Biochem, 2018, 119(6): 4717-4728.
|
| [7] |
Liu X, Meng L, Li X, et al. Regulation of FN1 degradation by the p62/SQSTM1-dependent autophagy-lysosome pathway in HNSCC[J]. Int J Oral Sci, 2020, 12(1): 34.
|
| [8] |
Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer[J]. Breast, 2015, 24 Suppl 2: S26-S35.
|
| [9] |
Li B, Yau T, Leung R, et al. Neoadjuvant therapy with concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) in high-risk HER2-negative breast cancers[J]. Adv Ther, 2021, 38(12): 5752-5762.
|
| [10] |
Shafei A, El-Bakly W, Sobhy A, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer[J]. Biomed Pharmacother, 2017, 95: 1209-1218.
|
| [11] |
Samaan TMA, Samec M, Liskova A, et al. Paclitaxel's mechanistic and clinical effects on breast cancer[J]. Biomolecules, 2019, 9(12): 789.
|
| [12] |
Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?[J]. Acta Oncol, 2000, 39(1): 33-39.
|
| [13] |
Rugo HS, Im SA, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(4): 573-584.
|
| [14] |
Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer[J]. Cancer Cell, 2020, 37(4): 496-513.
|
| [15] |
Derakhshani A, Rezaei Z, Safarpour H, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy[J]. J Cell Physiol, 2020, 235(4): 3142-3156.
|
| [16] |
Zhang H, Sun Z, Li Y, et al. MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells[J]. Biomed Pharmacother, 2017, 88: 285-292.
|
| [17] |
Zhang H, Chen X, Xue P, et al. FN1 promotes chondrocyte differentiation and collagen production via TGF-β/PI3K/Akt pathway in mice with femoral fracture[J]. Gene, 2021, 769: 145253.
|
| [18] |
Gao R, Feng Q, Tan G. microRNA-613 exerts anti-angiogenic effect on nasopharyngeal carcinoma cells through inactivating the AKT signaling pathway by down-regulating FN1[J]. Biosci Rep, 2019, 39(7): BSR20182196.
|
| [19] |
Wang H, Guo S, Kim SJ, et al. Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel[J]. Theranostics, 2021, 11(5): 2442-2459.
|
| [20] |
Karthikeyan S, Waters IG, Dennison L, et al. Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones[J]. J Clin Invest, 2021, 131(6): e143557.
|
| [21] |
Saatci O, Kaymak A, Raza U, et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer[J]. Nat Commun, 2020, 11(1): 2416.
|
| [22] |
Lambertini M, Pondé NF, Solinas C, et al. Adjuvant trastuzumab: A 10-year overview of its benefit[J]. Expert Rev Anticancer Ther, 2017, 17(1): 61-74.
|
| [23] |
Mackay A, Jones C, Dexter T, et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells[J]. Oncogene, 2003, 22(17): 2680-2688.
|